 The shares of Sage Therapeutics Inc NASDAQ:SAGE are down 1.8 at 72.78 at last check, after Raymond James downgraded the stock to Market Perform from Outperform, following its recent 1.5 billion deal with Biogen BIIB to develop therapies to treat depression and other neurological disorders. 